- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01393717
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. The primary objective of this study is to determine the activity of salvage brentuximab vedotin in Hodgkin lymphoma prior to autologous hematopoietic stem cell transplantation, as measured by overall response rate (ORR).
SECONDARY OBJECTIVES:
I. To describe the safety, toxicity, and tolerability of brentuximab vedotin as a salvage regimen.
II. To summarize the stem cell mobilization results of patients receiving brentuximab vedotin as salvage therapy (e.g., total cluster of differentiation (CD)34+ cell yield, number of apheresis days, proportion of patients who achieve >= 3 x 10^6 CD34+ cells/kg).
III. To evaluate potential changes in Hodgkin lymphoma biological markers of patients treated with brentuximab vedotin as first line salvage therapy.
IV. To examine and characterize the outcomes of patients who receive brentuximab vedotin as first line salvage followed by autologous hematopoietic stem cell transplantation (AHCT) (e.g., toxicity, 2-year progression free survival [PFS], overall survival [OS], relapse-progression incidence and non-relapse mortality rate [NRM])
OUTLINE:
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses.
Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving complete remission (CR) after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
After completion of study treatment, patients are followed up at 21 days.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Weill Medical College, Cornell University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma with CD 30 expression
- Patients must have absolute neutrophil count (ANC) >= 1000/uL; neupogen (filgrastim) can be given prior to start of SGN-35 (brentuximab vedotin) and during SGN-35 treatment to achieve target ANC >= 1000/uL
- Patients must have platelets (Plts) >= 50,000/uL; platelet transfusion can be given prior to the start of SGN-35 and during SGN-35 treatment to achieve a target plt >= 50,000/uL
- Patients must have measurable disease > 1.5 cm evidenced by computed tomography (CT) scan of the neck/chest/abdomen(abd)/pelvis or CT/positron emission tomography (PET) scans
- Patient must be either primary refractory to one frontline induction therapy or relapsed after one frontline induction therapy; patients who do not achieve complete remission after induction therapy are also eligible
- Patients cannot have had a second line salvage treatment (chemotherapy, biologic agents, investigational drugs, or radiation) or have had an autologous or allogeneic hematopoietic stem cell transplantation; patients can have had mixed frontline therapy such as 2-4 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) followed by 2-4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) as long as the induction chemotherapy is not more than 8 cycles in total length
- Radiation use as part of induction regimen or consolidation (within 90 days after completion of induction chemotherapy) is allowed
- Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
- Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
- Male subject agrees to use an acceptable method of contraception for the duration of the study
- Life expectancy of greater than 3 months
- Karnofsky performance status of > 60%
- ANC >= 1000/uL
- Plts >= 50,000/uL
- Total bilirubin within 1.5 x of the upper limit of normal (ULN) institutional limits, patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
- Calculated creatinine clearance >30 ml/min (unless demonstrated Hodgkin lymphoma involvement of the kidney)
ELIGIBILITY FOR 2.4 MG/KG DOSING IN THE NEW COHORT:
- In addition to the inclusion/exclusion criteria outlined, to be eligible for treatment with the higher 2.4 mg/kg dose of brentuximab vedotin in the new cohort of 20 additional patients, best response after 2 cycles of brentuximab vedotin administered at the 1.8 mg/kg dose, must be partial remission (PR) or stable disease (SD) as determined by radiographic imaging
Exclusion Criteria:
- Patient has > 1.5 x ULN total bilirubin, unless history of Gilbert's syndrome
- Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any electrocardiogram (ECG) abnormality at screening has to be documented by the investigator as not medically relevant
- Patient has hypersensitivity to brentuximab vedotin
- Female subject is pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
- Patient has received other investigational drugs within 14 days before treatment of treatment with brentuximab vedotin
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
- Patients with other active malignancies (no evidence of other cancer or life expectancy greater than 5 years) are ineligible for this study
- Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study
- Patients may be on steroids prior to initiation of treatment as long as by cycle 1 day 1 steroids use was tapered down less than or equal to 20 mg of prednisone.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment (brentuximab vedotin)
Patients receive brentuximab vedotin IV over 30 minutes on day 1.
Treatment repeats every 21 days for up to 4 courses.
Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
|
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Overall Response Rate Among Patients With Salvage Brentuximab Vedotin (BV)
Prazo: 21 days after completion of last course of study treatment, up to 5 years
|
The overall response rate is calculated as the percent of evaluable patients that have confirmed CR or PR by radiographic imaging, and the exact 95% confidence interval is calculated for this estimate.
Per Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) for target lesions and assessed by CT/PET scans: Complete Response (CR), complete disappearance of all detectable clinical and radiographic evidence of disease; Partial Response (PR), ≥50% decrease in the sum of the product of the diameters of up to six of the largest dominant nodes or nodal masses.
|
21 days after completion of last course of study treatment, up to 5 years
|
Complete Response (CR) Rate Among Patients With Salvage Brentuximab Vedotin (BV)
Prazo: 21 days after completion of last course of study treatment, up to 5 years
|
The CR rate is calculated as the percent of evaluable patients that have confirmed CR by radiographic imaging, and the exact 95% confidence interval is calculated for this estimate.
Per Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) for target lesions and assessed by CT/PET scans: Complete Response (CR), complete disappearance of all detectable clinical and radiographic evidence of disease.
|
21 days after completion of last course of study treatment, up to 5 years
|
Overall Response Rate in Cohort #2
Prazo: 21 days after completion of last course of study treatment, up to 5 years
|
The overall response rate is calculated as the percent of evaluable patients that have confirmed CR or PR by radiographic imaging, and the exact 95% confidence interval is calculated for this estimate.
Per Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) for target lesions and assessed by CT/PET scans: Complete Response (CR), complete disappearance of all detectable clinical and radiographic evidence of disease; Partial Response (PR), ≥50% decrease in the sum of the product of the diameters of up to six of the largest dominant nodes or nodal masses.
|
21 days after completion of last course of study treatment, up to 5 years
|
Complete Response (CR) Rate in Cohort #2
Prazo: 21 days after completion of last course of study treatment, up to 5 years
|
The CR rate is calculated as the percent of evaluable patients that have confirmed CR by radiographic imaging, and the exact 95% confidence interval is calculated for this estimate.
Per Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) for target lesions and assessed by CT/PET scans: Complete Response (CR), complete disappearance of all detectable clinical and radiographic evidence of disease.
|
21 days after completion of last course of study treatment, up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Total CD34+ Cell Dose Among Patients Receiving Brentuximab Vedotin Followed by Autologous Hematopoietic Stem Cell Transplantation
Prazo: 60 days after completion of last course of study treatment, up to conditioning regimens
|
Among the patients receiving salvage Brentuximab Vedotin (BV) followed by Autologous Hematopoietic Stem Cell Transplantation (AutoHCT), their total CD34+ cell yield by stem cell mobilization.
|
60 days after completion of last course of study treatment, up to conditioning regimens
|
Progression Free Survival at Year Two Among AutoHCT Patients With BV
Prazo: Assessed for up to 5 years, at least half of the surviving participants followed 2+ years
|
Progression Free Survival (PFS) defined as the time from first treatment day (post AHCT) until objective or symptomatic relapse or death as a result of lymphoma or acute toxicity of treatment.
Assessed by Kaplan-Meier survival analysis and 95% confidence intervals will be calculated using Greenwood's formula.
|
Assessed for up to 5 years, at least half of the surviving participants followed 2+ years
|
Overall Survival at Year Two Among AutoHCT Patients With BV
Prazo: Assessed for up to 5 years, at least half of the surviving participants followed 2+ years
|
Overall Survival (OS) defined as the time from first treatment day (post AHCT) until death.
Assessed by Kaplan-Meier survival analysis and 95% confidence intervals will be calculated using Greenwood's formula.
|
Assessed for up to 5 years, at least half of the surviving participants followed 2+ years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Robert Chen, City of Hope Medical Center
Publicações e links úteis
Publicações Gerais
- Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018 Mar 1;29(3):724-730. doi: 10.1093/annonc/mdx791.
- Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Linfoma
- Doença de Hodgkin
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Fatores imunológicos
- Agentes Antineoplásicos Imunológicos
- Anticorpos
- Imunoglobulinas
- Anticorpos Monoclonais
- Brentuximabe Vedotin
- Imunoconjugados
Outros números de identificação do estudo
- 11051
- NCI-2011-01135 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Linfoma de Hodgkin Recorrente
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Ativo, não recrutandoLinfoma Ann Arbor Estágio III Hodgkin | Linfoma Hodgkin Ann Arbor Estágio IIIA | Linfoma Ann Arbor Estágio IIIB Hodgkin | Linfoma de Hodgkin de Ann Arbor Estágio IV | Linfoma Ann Arbor Estágio IVA Hodgkin | Linfoma Ann Arbor Estágio IVB Hodgkin | Linfoma de Hodgkin Clássico | Linfoma Ann Arbor Estágio... e outras condiçõesEstados Unidos
-
National Cancer Institute (NCI)ConcluídoLinfoma de Hodgkin adulto recorrente | Linfoma de Hodgkin adulto estágio III | Linfoma de Hodgkin Adulto Estágio IV | Linfoma de Hodgkin infantil recorrente/refratário | Linfoma de Hodgkin na Infância Estágio III | Linfoma de Hodgkin na Infância Estágio IV | Linfoma de Hodgkin Adulto Estágio I | Linfoma... e outras condiçõesEstados Unidos
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Ativo, não recrutandoLinfoma de Hodgkin Clássico | Linfoma Ann Arbor Estágio IB Hodgkin | Linfoma Ann Arbor Estágio II de Hodgkin | Linfoma Ann Arbor Estágio IIA Hodgkin | Linfoma Ann Arbor Estágio IIB Hodgkin | Linfoma Ann Arbor Estágio I Hodgkin | Linfoma Ann Arbor Estágio IA HodgkinEstados Unidos
-
National Cancer Institute (NCI)Ativo, não recrutandoLinfoma Ann Arbor Estágio IIIB Hodgkin | Linfoma Ann Arbor Estágio IVA Hodgkin | Linfoma Ann Arbor Estágio IVB Hodgkin | Linfoma de Hodgkin Clássico | Linfoma Ann Arbor Estágio IIB Hodgkin | Linfoma de Hodgkin na InfânciaEstados Unidos, Canadá, Porto Rico
-
Marker Therapeutics, Inc.RecrutamentoLinfoma Não Hodgkin | Linfoma Não-Hodgkin Adulto | Linfoma Não-Hodgkin Refratário | Linfoma não-Hodgkin recidivanteEstados Unidos
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityConcluídoLinfoma de Hodgkin Adulto | Linfoma Não-Hodgkin AdultoFederação Russa
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RescindidoLinfoma de Hodgkin Recorrente | Linfoma de Hodgkin refratário | Linfoma não Hodgkin de células B refratário | Linfoma Não Hodgkin de Células T Refratário | Linfoma não Hodgkin recorrente de células B | Linfoma não Hodgkin recorrente de células TEstados Unidos
-
National Cancer Institute (NCI)The Lymphoma Academic Research OrganisationAtivo, não recrutandoInfecção pelo HIV | Linfoma Ann Arbor Estágio III Hodgkin | Linfoma Hodgkin Ann Arbor Estágio IIIA | Linfoma Ann Arbor Estágio IIIB Hodgkin | Linfoma de Hodgkin de Ann Arbor Estágio IV | Linfoma Ann Arbor Estágio IVA Hodgkin | Linfoma Ann Arbor Estágio IVB Hodgkin | Linfoma de Hodgkin Clássico | Linfoma... e outras condiçõesEstados Unidos, França
-
Northwestern UniversitySeagen Inc.; Robert H. Lurie Cancer CenterDesconhecidoLinfoma de Hodgkin adulto estágio III | Linfoma de Hodgkin Adulto Estágio IV | Linfoma de Hodgkin adulto estágio II | Linfoma de Hodgkin com Depleção de Linfócitos Adultos | Linfoma de Hodgkin predominante de linfócitos adultos | Linfoma Hodgkin de Celularidade Mista Adulto | Adulto Linfoma de Hodgkin...Estados Unidos
-
Shanghai Zhongshan HospitalRecrutamentoLinfoma | Linfoma de Hodgkin | Linfoma Não HodgkinChina
Ensaios clínicos em brentuximabe vedotina
-
Fondazione Italiana Linfomi ONLUSConcluídoLinfoma de Hodgkin recidivante/refratárioItália
-
Tianjin Medical University Second HospitalRecrutamentoCarcinoma Urotelial de Bexiga Invasivo Não Muscular de Alto Risco Her2China
-
RemeGen Co., Ltd.Recrutamento
-
University Hospital, CaenRecrutamento
-
RenJi HospitalRecrutamento
-
AbbVieAtivo, não recrutandoCâncer de Pulmão de Células Não PequenasEstados Unidos, Austrália, França, Alemanha, Israel, Itália, Japão, Republica da Coréia, Taiwan
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma US, Inc.RecrutamentoCarcinoma UrotelialEstados Unidos
-
Astellas Pharma Korea, Inc.Seagen Inc.RecrutamentoCâncer UrotelialRepublica da Coréia
-
Wuhan Union Hospital, ChinaRecrutamentoCâncer de mama | Terapia NeoadjuvanteChina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Ainda não está recrutando